Book contents
- Frontmatter
- Contents
- List of figures
- List of tables
- List of contributors
- Acknowledgments
- 1 Introduction
- Part I Innovation and industry evolution
- 2 Pharmaceutical innovation as a process of creative destruction
- 3 The evolution of pharmaceutical innovation
- 4 Firm and regional determinants in innovation models: evidence from biotechnology and traditional chemicals
- 5 Innovation and industry evolution: a comment
- Part II Firm growth and market structure
- Part III Policy implications
- Index
- References
4 - Firm and regional determinants in innovation models: evidence from biotechnology and traditional chemicals
Published online by Cambridge University Press: 22 September 2009
- Frontmatter
- Contents
- List of figures
- List of tables
- List of contributors
- Acknowledgments
- 1 Introduction
- Part I Innovation and industry evolution
- 2 Pharmaceutical innovation as a process of creative destruction
- 3 The evolution of pharmaceutical innovation
- 4 Firm and regional determinants in innovation models: evidence from biotechnology and traditional chemicals
- 5 Innovation and industry evolution: a comment
- Part II Firm growth and market structure
- Part III Policy implications
- Index
- References
Summary
Introduction
Firm competencies are discussed in the literature as important sources of firms' competitive advantage. They develop over time and, together with specific routines and communication mechanisms internal to the organization, affect the direction and the outcome of firms' R&D activities (see, for example, Nelson and Winter, 1982, and Dosi et al., 1988).
Recently, however, the economic literature has highlighted the importance of an alternative model for organizing production and innovative activities: the geographical proximity among researchers and institutions in a technological cluster. The contributions on regional clustering and geographically localized knowledge spillovers argue that the cost of transferring knowledge increases with the geographical distance among the parties involved in the exchange. This explains the tendency of innovative activities to locate together (see, for example, Jaffe, 1986; Jaffe, Trajtenberg, and Henderson, 1993; Audretsch and Feldman, 1996; and Swann, Prevezer, and Stout 1998).
So far the literature has analyzed these issues separately. This chapter recombines these two streams of the literature and compares their relative importance in explaining a research output: the value of innovations. It estimates how much of the value of an innovation is affected by the affiliation of the inventors to the same organization, as opposed to spillovers that arise when the inventors are geographically close to each other and to external sources of knowledge. In so doing it expands upon a previous paper by Mariani (2004).
- Type
- Chapter
- Information
- Knowledge Accumulation and Industry EvolutionThe Case of Pharma-Biotech, pp. 112 - 144Publisher: Cambridge University PressPrint publication year: 2006
References
- 1
- Cited by